Oral therapies for psoriasis and psoriatic arthritis: current knowledge and future perspectives

2020 ◽  
Vol 155 (4) ◽  
Author(s):  
Tiago Torres
Keyword(s):  
Psoriatic Arthritis ◽  
Current Knowledge ◽  
Future Perspectives

Pulmonary Manifestations in Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis Prevalence, Diagnostic Approach and Treatment Options

2020 ◽  
Vol 16 ◽  
Author(s):  
Daniel Dejcman ◽  
Valentin Sebastian Schäfer ◽  
Dirk Skowasch ◽  
Carmen Pizarro ◽  
Andreas Krause ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Lung Disease ◽  
Current Knowledge ◽  
Treatment Options ◽  
Pulmonary Diseases ◽  
Chronic Obstructive ◽  
Pulmonary Manifestations ◽  
Major Cluster ◽  
Peripheral Spondyloarthritis

: Interstitial lung disease (ILD) is the most common form of pulmonary impairment in patients with rheumatoid arthritis (RA). However, patients with RA or other arthritic diseases such as psoriatic arthritis (PsA) or peripheral spondyloarthritis (pSpA) may develop several other pulmonary diseases such as chronic obstructive lung disease (COPD) with a higher risk than patients without arthritis. The article at hand aims at summarizing the current knowledge on the prevalence of pulmonary diseases in the above-mentioned forms of arthritis, the challenges for prevalence studies and detecting pulmonary diseases in patients with arthritis as well as possible treatment options. Dyspnea, cough or other pulmonary symptoms or findings in arthritis patients should prompt gradual diagnostic procedures considering pulmonary manifestations as a major cluster of differential diagnosis. Considering its poor prognosis and morbidity burden, RA-ILD needs to be ruled out. Treatment of manifestations often lacks solid evidencebased guidelines and referrals to specialized centers are often necessary.

scholarly journals The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1266
Author(s):  
Andreja Figurek ◽  
Merita Rroji ◽  
Goce Spasovski
Keyword(s):  
Chronic Kidney Disease ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Current Knowledge ◽  
Fibroblast Growth Factor 23 ◽  
Mechanisms Of Action ◽  
Fibroblast Growth ◽  
Normal Kidney ◽  
Future Perspectives ◽  
Therapeutic Possibilities

Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD). This review summarizes the current knowledge of FGF23 mechanisms of action in the myocardium in the physiological and pathophysiological state of CKD, as well as its cross-talk to other important signaling pathways in cardiomyocytes. In this regard, current therapeutic possibilities and future perspectives are also discussed.

Sulfur aerosols in the Arctic, Antarctic, and Tibetan Plateau: Current knowledge and future perspectives

2021 ◽  
pp. 103753
Author(s):  
Qiaomin Pei ◽  
Eri Saikawa ◽  
Susan Kaspari ◽  
David Widory ◽  
Chuanfeng Zhao ◽  
...  
Keyword(s):  
Tibetan Plateau ◽  
Current Knowledge ◽  
The Arctic ◽  
Future Perspectives

scholarly journals Magnetic Resonance Imaging in Psoriatic Arthritis — Update on Current Status and Future Perspectives: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 408-412 ◽  
Author(s):  
MIKKEL ØSTERGAARD ◽  
RENÉ PANDURO POGGENBORG
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Annual Meeting ◽  
Current Status ◽  
Future Research ◽  
Future Perspectives ◽  
Resonance Imaging ◽  
Primary Driver ◽  
Magnetic Resonance Imaging Mri

The potential of magnetic resonance imaging (MRI) for use in clinical practice and research has gained increasing interest over the last decade. International collaborative initiatives from GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and/or OMERACT (Outcome Measures in Rheumatology) may contribute to facilitating research, identifying appropriate areas for use, and reaching consensus on the optimal examination technique. Accordingly, GRAPPA, a primary driver of international research in psoriasis and psoriatic arthritis (PsA), has focused on the current use and future development of MRI and other modern imaging modalities in PsA. This review, presented at the GRAPPA 2010 annual meeting, describes the current status of MRI in PsA, with a focus on its use in diagnosis, monitoring, and prediction of the disease course and treatment response. Important areas for future research are also outlined.

Sign in / Sign up

Export Citation Format

Share Document